References analysis of the Wikipedia article "Dienogest" in the English version

books.google.com

Stanczyk FZ, Bretsky (22 May 2013). "Biosynthesis, Transport, and Metabolism of Steroid Hormones". In Falcone T, Hurd WW (eds.). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer Science & Business Media. pp. 300–. ISBN 978-1-4614-6837-0. Dienogest is a 19-nortestosterone derivative that is approved in the European Union for the treatment of endometriosis. It is not available in the United States as a separate drug. It is only available in the oral contraceptive Natazia (Bayer Pharmaceuticals, Montville, NJ, USA) (estradiol valerate/dienogest), which is a newer four-phasic pack that contains dienogest.

Hall S, Gebbie AE (11 July 2013). "Progestogens used in Contraceptives". In Briggs P, Kovacs G (eds.). Contraception: A Casebook from Menarche to Menopause. Cambridge University Press. pp. 52–. ISBN 978-1-107-43611-4.

Bitzer J (9 April 2015). "Progestogens in Contraception". In Carp HJ (ed.). Progestogens in Obstetrics and Gynecology. Springer. pp. 112–113, 170–. ISBN 978-3-319-14385-9.

Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (25 August 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. pp. 2938–. ISBN 978-1-4160-6911-9.

Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 390–. ISBN 978-1-4757-2085-3.

Brucker MC, Likis FE (8 September 2015). "Steroid Hormones". In Brucker MC, King TL (eds.). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 368–. ISBN 978-1-284-05748-5.

Melo J, Creinin MD (28 September 2015). "Combination Oral Contraceptive Pills". In Shoupe D, Mishell Jr DR (eds.). The Handbook of Contraception: A Guide for Practical Management. Humana Press. pp. 63–. ISBN 978-3-319-20185-6.

doi.org

Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.

Ruan X, Seeger H, Mueck AO (April 2012). "The pharmacology of dienogest". Maturitas. 71 (4): 337–344. doi:10.1016/j.maturitas.2012.01.018. PMID 22364708.

Bińkowska M, Woroń J (June 2015). "Progestogens in menopausal hormone therapy". Przeglad Menopauzalny = Menopause Review. 14 (2): 134–143. doi:10.5114/pm.2015.52154. PMC 4498031. PMID 26327902.

Bizzarri N, Remorgida V, Leone Roberti Maggiore U, Scala C, Tafi E, Ghirardi V, et al. (September 2014). "Dienogest in the treatment of endometriosis". Expert Opinion on Pharmacotherapy. 15 (13): 1889–1902. doi:10.1517/14656566.2014.943734. PMID 25069386. S2CID 37627607.

Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264.

Foster RH, Wilde MI (November 1998). "Dienogest". Drugs. 56 (5): 825–33, discussion 834–5. doi:10.2165/00003495-199856050-00007. PMID 9829156. S2CID 262326901.

McCormack PL (November 2010). "Dienogest: a review of its use in the treatment of endometriosis". Drugs. 70 (16): 2073–2088. doi:10.2165/11206320-000000000-00000. PMID 20964453. S2CID 249871173.

Micks EA, Jensen JT (January 2013). "Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill". Advances in Therapy. 30 (1): 1–13. doi:10.1007/s12325-012-0071-3. PMID 23239397. S2CID 31125733.

"Dienogest". Australian Prescriber. 38 (4): 138–139. August 2015. doi:10.18773/austprescr.2015.050. PMC 4653971. PMID 26648643.

Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–492. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.

Regidor PA, Schindler AE (October 2017). "Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone". Oncotarget. 8 (47): 83334–83342. doi:10.18632/oncotarget.19833. PMC 5669973. PMID 29137347.

Menzenbach B, Hübner M, Ponsold K (1984). "Untersuchungen zur Bromierung/Dehydrobromierung von 17-Cyanmethyl-17-hydroxy-östr-5(10)-en-3-on". Journal für Praktische Chemie. 326 (6): 893–898. doi:10.1002/prac.19843260606.

Kaufmann G, Dautzenberg H, Henkel H, Müller G, Schäfer T, Undeutsch B, Oettel M (August 1999). "Nitrile hydratase from Rhodococcus erythropolis: metabolization of steroidal compounds with a nitrile group". Steroids. 64 (8): 535–540. doi:10.1016/S0039-128X(99)00028-8. PMID 10493599. S2CID 21769309.

Guida M, Bifulco G, Di Spiezio Sardo A, Scala M, Fernandez LM, Nappi C (August 2010). "Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill". International Journal of Women's Health. 2: 279–290. doi:10.2147/IJWH.S6954. PMC 2990895. PMID 21151673.

Pérez-Campos EF (April 2010). "Ethinylestradiol/dienogest in oral contraception". Drugs. 70 (6): 681–689. doi:10.2165/11536320-000000000-00000. PMID 20394455. S2CID 46374974.

Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H (June 2006). "Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest". Fertility and Sterility. 85 (6): 1812–1819. doi:10.1016/j.fertnstert.2005.11.052. PMID 16759929.

Hoy SM, Scott LJ (August 2009). "Estradiol valerate/dienogest: in oral contraception". Drugs. 69 (12): 1635–1646. doi:10.2165/11202820-000000000-00000. PMID 19678714. S2CID 207297417.

Whalen KL, Rose R (October 2011). "Estradiol valerate/dienogest: a novel oral contraceptive". The Annals of Pharmacotherapy. 45 (10): 1256–1261. doi:10.1345/aph.1Q216. PMID 21917554. S2CID 33366375.

Fruzzetti F, Trémollieres F, Bitzer J (May 2012). "An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest". Gynecological Endocrinology. 28 (5): 400–408. doi:10.3109/09513590.2012.662547. PMC 3399636. PMID 22468839.

Andres M, Lopes LA, Baracat EC, Podgaec S (September 2015). "Dienogest in the treatment of endometriosis: systematic review". Archives of Gynecology and Obstetrics. 292 (3): 523–529. doi:10.1007/s00404-015-3681-6. PMID 25749349. S2CID 22168242.

Wiegratz I, Lee JH, Kutschera E, Bauer HH, von Hayn C, Moore C, et al. (March 2002). "Effect of dienogest-containing oral contraceptives on lipid metabolism". Contraception. 65 (3): 223–229. doi:10.1016/S0010-7824(01)00310-9. PMID 11929644.

Fruzzetti F, Cagnacci A (2018). "Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?". Open Access Journal of Contraception. 9: 75–79. doi:10.2147/OAJC.S179673. PMC 6239102. PMID 30519125.

Wiegratz I, Kuhl H (September 2006). "Metabolic and clinical effects of progestogens". The European Journal of Contraception & Reproductive Health Care. 11 (3): 153–161. doi:10.1080/13625180600772741. PMID 17056444. S2CID 27088428.

Meriggiola MC, Bremner WJ, Costantino A, Bertaccini A, Morselli-Labate AM, Huebler D, et al. (May 2002). "Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men". The Journal of Clinical Endocrinology and Metabolism. 87 (5): 2107–2113. doi:10.1210/jcem.87.5.8514. hdl:1773/4465. PMID 11994349.

Nieschlag E, Zitzmann M, Kamischke A (November 2003). "Use of progestins in male contraception". Steroids. 68 (10–13): 965–972. doi:10.1016/S0039-128X(03)00135-1. PMID 14667989. S2CID 22458746.

Knuth UA, Hano R, Nieschlag E (November 1984). "Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men". The Journal of Clinical Endocrinology and Metabolism. 59 (5): 963–969. doi:10.1210/jcem-59-5-963. PMID 6237116.

Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (June 1980). "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". British Journal of Urology. 52 (3): 208–215. doi:10.1111/j.1464-410x.1980.tb02961.x. PMID 7000222.

Sander S, Nissen-Meyer R, Aakvaag A (1978). "On gestagen treatment of advanced prostatic carcinoma". Scandinavian Journal of Urology and Nephrology. 12 (2): 119–121. doi:10.3109/00365597809179977. PMID 694436.

Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, et al. (November 1979). "Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men". Clinical Endocrinology. 11 (5): 497–504. doi:10.1111/j.1365-2265.1979.tb03102.x. PMID 519881. S2CID 5836155.

Sitruk-Ware R, Husmann F, Thijssen JH, Skouby SO, Fruzzetti F, Hanker J, et al. (September 2004). "Role of progestins with partial antiandrogenic effects". Climacteric. 7 (3): 238–254. doi:10.1080/13697130400001307. PMID 15669548. S2CID 23112620.

Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, et al. (October 2013). "Possible role of PGRMC1 in breast cancer development". Climacteric. 16 (5): 509–513. doi:10.3109/13697137.2013.800038. PMID 23758160. S2CID 29808177.

Trabert B, Sherman ME, Kannan N, Stanczyk FZ (April 2020). "Progesterone and Breast Cancer". Endocrine Reviews. 41 (2): 320–344. doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725.

Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Current Medicinal Chemistry. 7 (2): 211–247. doi:10.2174/0929867003375371. PMID 10637363.

Bergink EW, Loonen PB, Kloosterboer HJ (August 1985). "Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties". Journal of Steroid Biochemistry. 23 (2): 165–168. doi:10.1016/0022-4731(85)90232-8. PMID 3928974.

Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". Journal of Steroid Biochemistry. 27 (1–3): 255–269. doi:10.1016/0022-4731(87)90317-7. PMID 3695484.

Schubert K, Schumann G, Kaufmann G (January 1983). "Influence of a 9-double bond on stereospecific microbial 4,5-reductions". Journal of Steroid Biochemistry. 18 (1): 75–80. doi:10.1016/0022-4731(83)90333-3. PMID 6683343.

Hobe G, Schön R, Hajek M, Undisz K, Härtl A (1998). "Studies on the hydrogenation of the progestagen dienogest in vivo and in vitro in the female rabbit". Steroids. 63 (7–8): 393–400. doi:10.1016/s0039-128x(98)00014-2. PMID 9654645. S2CID 9659302.

Oettel M, Kurischko A (January 1980). "STS 557, a new orally active progestin with antiprogestational and contragestational properties in rabbits". Contraception. 21 (1): 61–69. doi:10.1016/0010-7824(80)90140-7. PMID 7357870.

Manetti GJ, Honig SC (2010). "Update on male hormonal contraception: is the vasectomy in jeopardy?". International Journal of Impotence Research. 22 (3): 159–170. doi:10.1038/ijir.2010.2. PMID 20336073. S2CID 21283244.

Misro MM, Chaki SP, Kaushik MC, Nandan D (June 2009). "Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats". Contraception. 79 (6): 488–497. doi:10.1016/j.contraception.2009.01.003. PMID 19442786.

Paslakis G, Maas S, Gebhardt B, Mayr A, Rauh M, Erim Y (April 2018). "Prospective, randomized, double-blind, placebo-controlled phase IIa clinical trial on the effects of an estrogen-progestin combination as add-on to inpatient psychotherapy in adult female patients suffering from anorexia nervosa". BMC Psychiatry. 18 (1): 93. doi:10.1186/s12888-018-1683-1. PMC 5891970. PMID 29631553.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ruan X, Seeger H, Mueck AO (April 2012). "The pharmacology of dienogest". Maturitas. 71 (4): 337–344. doi:10.1016/j.maturitas.2012.01.018. PMID 22364708.

Bińkowska M, Woroń J (June 2015). "Progestogens in menopausal hormone therapy". Przeglad Menopauzalny = Menopause Review. 14 (2): 134–143. doi:10.5114/pm.2015.52154. PMC 4498031. PMID 26327902.

Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264.

Foster RH, Wilde MI (November 1998). "Dienogest". Drugs. 56 (5): 825–33, discussion 834–5. doi:10.2165/00003495-199856050-00007. PMID 9829156. S2CID 262326901.

McCormack PL (November 2010). "Dienogest: a review of its use in the treatment of endometriosis". Drugs. 70 (16): 2073–2088. doi:10.2165/11206320-000000000-00000. PMID 20964453. S2CID 249871173.

"Dienogest". Australian Prescriber. 38 (4): 138–139. August 2015. doi:10.18773/austprescr.2015.050. PMC 4653971. PMID 26648643.

Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–492. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.

Pérez-Campos EF (April 2010). "Ethinylestradiol/dienogest in oral contraception". Drugs. 70 (6): 681–689. doi:10.2165/11536320-000000000-00000. PMID 20394455. S2CID 46374974.

Hoy SM, Scott LJ (August 2009). "Estradiol valerate/dienogest: in oral contraception". Drugs. 69 (12): 1635–1646. doi:10.2165/11202820-000000000-00000. PMID 19678714. S2CID 207297417.

Nieschlag E, Zitzmann M, Kamischke A (November 2003). "Use of progestins in male contraception". Steroids. 68 (10–13): 965–972. doi:10.1016/S0039-128X(03)00135-1. PMID 14667989. S2CID 22458746.

Trabert B, Sherman ME, Kannan N, Stanczyk FZ (April 2020). "Progesterone and Breast Cancer". Endocrine Reviews. 41 (2): 320–344. doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264.

Foster RH, Wilde MI (November 1998). "Dienogest". Drugs. 56 (5): 825–33, discussion 834–5. doi:10.2165/00003495-199856050-00007. PMID 9829156. S2CID 262326901.

McCormack PL (November 2010). "Dienogest: a review of its use in the treatment of endometriosis". Drugs. 70 (16): 2073–2088. doi:10.2165/11206320-000000000-00000. PMID 20964453. S2CID 249871173.

Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–492. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.

Pérez-Campos EF (April 2010). "Ethinylestradiol/dienogest in oral contraception". Drugs. 70 (6): 681–689. doi:10.2165/11536320-000000000-00000. PMID 20394455. S2CID 46374974.

Hoy SM, Scott LJ (August 2009). "Estradiol valerate/dienogest: in oral contraception". Drugs. 69 (12): 1635–1646. doi:10.2165/11202820-000000000-00000. PMID 19678714. S2CID 207297417.

Nieschlag E, Zitzmann M, Kamischke A (November 2003). "Use of progestins in male contraception". Steroids. 68 (10–13): 965–972. doi:10.1016/S0039-128X(03)00135-1. PMID 14667989. S2CID 22458746.

Dienogest (English Wikipedia)

bayerhealthcare.com

labeling.bayerhealthcare.com

books.google.com

cbg-meb.nl

db.cbg-meb.nl

doi.org

drugs.com

handle.net

hdl.handle.net

jenapharm.de

jmdrev.com

nelm.nhs.uk

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nps.org.au

semanticscholar.org

api.semanticscholar.org

springer.com

adisinsight.springer.com

tga.gov.au

ebs.tga.gov.au

web.archive.org